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Background/aim: From a pathophysiological point of view, inflammation is thought to be more dominant in bicuspid aortic valve
(BAV) stenosis than tricuspid aortic valve (TAV) stenosis. Our study aimed to determine the association between monocyte to highdensity lipoprotein cholesterol (HDL-C) ratio (MHR), a new inflammatory marker, and the speed of progression of stenosis and
pathophysiology of BAV stenosis.
Materials and methods: A total of 210 severe aortic stenosis patients (70 consecutive BAV patients, 140 matched TAV patients) were
retrospectively enrolled in the study. Clinical and echocardiographic data and laboratory results related to our research were collected
retrospectively from the patients’ records. MHR was measured as the ratio of the absolute monocyte count to the HDL-C value.
Results: Seventy BAV (mean age: 72.0 ± 9.1 years, 42.9% female) and 140 TAV patients (mean age: 77.9 ± 8.3 years, 51.4% female)
with severe aortic stenosis were enrolled in this study. There was no difference between the two groups in terms of another baseline
demographic or clinic findings except age (P < 0.001). Monocyte count, hemoglobin level, mean platelet volume was significantly
higher, and HDL-C level was significantly lower in the BAV group, while other lipid and CBC parameters were found to be similar. In
the multivariate analysis, MHR (P = 0.005, 95% CI: 0.90–0.98) and, as expected, age (P = 0.001, 95% CI: 1.02–1.11) were found to be
significant as the independent predictor of BAV, after adjusting for other risk factors.
Conclusion: Our study showed a significant correlation between increased MHR and BAV. MHR was determined as a significant
independent predictor for the speed of progression and diagnosis of severe BAV stenosis in multivariate analysis.
Key words: Bicuspid aortic valve, tricuspid aortic valve, aortic stenosis, monocyte to high-density lipoprotein cholesterol ratio,
inflammation

1. Introduction
Bicuspid aortic valve (BAV) is the most common
congenital heart anomaly in adults, and its prevalence has
been reported to be 1–2% [1]. BAV usually coexists with
other obstructive diseases such as aortic coarctation, or
with hypoplastic left heart, interrupted aortic arch, and
noncompaction cardiomyopathy [2]. BAV is associated
with a faster aortic valve degeneration, resulting in aortic
valve stenosis (AS), or insufficiency [3].
Calcific aortic valve disease is progressive and present
in 20–30% of patients aged over 65 years, and 48% of
patients over 85 years, also AS affects 2–3% of patients
under 65 years and 8% of patients over 85 years [4].
Calcific AS was thought to be a passive and degenerative
process that progresses with age. Still, recent data
indicate that chronic inflammation plays a role, similar

to the pathophysiology of coronary atherosclerosis [5].
Albeit a genetic predisposition has been detected in the
development of tricuspid aortic valve (TAV) stenosis,
besides the mechanical stress caused by minor changes in
cusp size; the combination of atherosclerotic risk factors
such as diabetes mellitus (DM), hypertension (HT),
hyperlipidemia (HL), age, and smoking habit plays a role
in the onset of valve stenosis [6,7].
Compared to TAV stenosis, BAV stenosis develops
earlier in life. Over recent years, significant attention has
been paid to explain BAV pathogenesis and complications,
including the addition of genetics and inflammation.
Atherosclerotic risk factors such as hyperlipidemia (HL)
and HT are associated with the development of AS in BAV
[8]. Moreover, some but not all researchers have presented
evidence of systemic inflammatory activation in BAV [9].
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Monocyte activation plays a vital role in chronic
inflammation and cardiovascular diseases by modulating
inflammatory cytokines [10]. High-density lipoprotein
cholesterol (HDL-C) is highly valuable in inhibiting
endothelial expression of adhesion molecules and
preventing monocyte uptake into the arterial wall.
Therefore, the monocyte-to-HDL-C ratio (MHR) is a
simple estimation method to predict inflammation and
reported as a significant predictor of cardiovascular
diseases in recent studies [11]. Thus, this study is aimed to
analyze the potential role of typical inflammatory markers
like MHR on the diagnosis, the speed of progression,
diagnosis of severe BAV stenosis, and pathophysiology of
BAV stenosis.
2. Materials and methods
2.1. Study population
We enrolled retrospectively 70 consecutive BAV patients
who were admitted to our clinic between January 2012
and October 2018 along with 140 sex, DM, HT, HL, body
mass index matched TAV patients diagnosed with severe
AS. According to echocardiographic findings, we thought
that BAVs were isolated congenital lesions. Baseline
characteristics of patients, clinical and echocardiographic
data, and laboratory results related to our study were
collected retrospectively from the hospital information
management system as well as patient files. When
echocardiographic results were examined; those who met
these criteria—aortic valve area (AVA) <1.0 cm2 or mean
gradient >40 mmHg or maximum jet velocity >4.0 m/s,
AVA index <0.6 cm2/m2—were considered as severe AS.
Diagnosis of the BAV was made by visualizing two aortic
leaflets clearly in the transthoracic parasternal short-axis
image, irrespective of the presence of raphe. The BAV and
TAV patients with presence of rheumatic or congenital
disease, severe mitral/tricuspid valve disease, acute or
history infective endocarditis, obstructive coronary
artery disease, hemodynamically significant arrhythmias,
malignancies, hepatic, renal or hematologic severe diseases
including leucocythemia and acute or chronic infection or
inflammatory condition were excluded from the study.
The local ethics committee approved the study.
2.2. Laboratory examination of the blood
Peripheral blood samples were drawn from a large
antecubital vein for detection of complete blood count
(CBC), total serum cholesterol (TC), triglycerides (TGs),
HDL cholesterol, and low-density lipoprotein (LDL)
cholesterol and plasma glucose (Symex K-1000, Kobe,
Japan) on admission. All routine biochemical analyses
were performed using an autoanalyzer (Roche Diagnostic
Modular Systems, Tokyo, Japan). Monocyte count was
defined by differential analysis of complete blood count,
and the MHR was measured as the ratio of the absolute
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monocyte count to the HDL-cholesterol value. NLR was
calculated as the ratio of the absolute neutrophil count
to the lymphocyte count. In our laboratory, the reference
value for monocyte was 0–0.9 K/uL.
2.3. Statistical analysis
All statistical analyses were applied in SPSS version 22.0
Windows (SPSS Inc, Chicago, Illinois). A two-tailed P-value
<0.05 was considered statistically significant. Categorical
variables are presented as numbers and percentages and
were compared by use of the chi-square test and Fisher’s
exact test. Continuous variables are expressed as mean
± SD and were compared normally distributed variables
with Student’s t-test and nonnormally distributed variables
with the Wilcoxon rank-sum test. Multivariable logistic
regression analyses were performed for all the variables
that were statistically different in the univariate analysis to
identify the independent risk factors of diagnosis BAV in
the study population.
3. Results
Seventy BAV (mean age: 72.0 ± 9.1 years, 42.9% female)
and 140 TAV patients (mean age: 77.9 ± 8.3 years, 51.4%
female) with severe AS were enrolled in this study. The
patients in the BAV group were younger than those in the
TAV group (P < 0.001); besides this, there was no difference
between the two groups in terms of another baseline
demographic or clinic findings. Comparison of baseline
demographic, clinical, and laboratory data between BAV
and TAV patients were represented in Table 1.
Monocyte count, hemoglobin level, mean platelet
volume were significantly higher, and HDL-C level was
significantly lower in the BAV group, while other lipid and
CBC parameters were found to be similar. Nevertheless,
a numerically higher rate of NLR was found in the BAV
group compared with the TAV group, and MHR was
statistically significantly higher in the BAV group (17.6 ±
10.1 vs. 12.4 ± 6.6, P = <0.001). Laboratory parameters are
shown in Table 2.
Table 3 presents comparison of baseline
echocardiographic parameters of all groups. There was
no significant difference observed between the groups
concerning left ventricle ejection fraction (LVEF), aortic
mean gradient, and aortic valve area (P > 0.05); however,
left ventricular end-diastolic diameter, left ventricular endsystolic diameter, aortic annulus, and systolic pulmonary
artery pressure (sPAP) were different between the groups.
In the multivariate analysis, MHR (P = 0.005, 95%
CI: 0.90–0.98) and, as expected, age (P = 0.001, 95%CI:
1.02–1.11) were found to be significant as the independent
predictor of BAV, after adjusting for other risk factors (Table
4). Moreover, NLR, LVEF, and other lipid parameters had
no predictive value for BAV compared to TAV stenosis.
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Table 1. Baseline clinical and laboratory parameters.

Parameters

All patients
n = 210

Group 1
BAV
n = 70

Group 2
TAV
n = 140

P-value

Age (years)

75.9 ± 9.0

72.0 ± 9.1

77.9 ± 8.3

<0.001

Female n (%)

102 (48.6)

30 (42.9)

72 (51.4)

0.241

BMI (kg/m )

27.1 ± 4.7

27.2 ± 4.8

27.0 ± 4.6

0.801

NYHA n (%)
-2
-3
-4

64 (30.5)
123 (58.5)
23 (11.0)

20 (28.6)
42 (60.0)
8 (11.4)

44 (31.4)
81 (65.9)
15 (10.7)

DM n (%)

66 (31.4)

27 (38.6)

39 (27.9)

0.115

HT n (%)

171 (81.4)

53 (75.7)

118 (84.3)

0.132

HL n (%)

112 (53.3)

35 (50.0)

77 (55.0)

0.494

Current smoker n (%)

58 (27.6)

18 (25.7)

40 (28.5)

0.684

Previous PCI n (%)

45 (21.4)

16 (22.9)

29 (20.7)

0.721

Previous CABG n (%)

55 (26.2)

19 (27.1)

36 (25.7)

0.824

Previous MI n (%)

27 (12.9)

12 (17.1)

15 (10.7)

0.190

Moderate to severe COPD n (%)

87 (41.4)

44 (48.6)

53 (37.9)

0.315

AF n (%)

46 (21.9)

14 (20.0)

32 (22.9)

0.637

Stroke n (%)

14 (6.7)

3 (4.3)

11 (7.9)

0.328

CAD
- Normal
- Nonobstructive

60 (28.6)
90 (42.9)

21 (30.0)
32 (45.7)

39 (27.9)
58 (41.4)

0.057

Medication n (%)
- RAS blocker
- Statin
- Beta blocker
- ASA
- OAC

153 (72.8)
106 (50.4)
80 (38.1)
151 (72.9)
49 (23.7)

45 (64.2)
28 (40.0)
23 (32.8)
54 (79.4)
12 (17.6)

108 (77.1)
78 (55.7)
57 (40.7)
97 (69.8)
37 (26.7)

2

0.711

0.135

BMI: Body Mass Index; NYHA: New York Heart Association; DM: Diabetes Mellitus; HT: Hypertension; PCI:
Percutaneous Coronary Intervention, CABG: Coronary artery Bypass Grafting, MI: Myocardial Infarction,
COPD: Chronic Obstructive Pulmonary Disease, AF: Atrial Fibrillation; CAD: Coronary Artery Disease; RAS:
Renin-angiotensin-system; ASA: Acetyl salicylic acid; OAC: Oral anticoagulant

4. Discussion
The main findings of our study are: 1) The MHR was found
to be significantly higher in patients with BAV compared
to TAV; 2) BAV patients were younger than TAV patients;
and 3) MHR was determined as a significant independent
predictor for diagnosis of severe BAV stenosis in
multivariate analysis.
The underlying eccentric valve structure and leaflet
matrix in the bicuspid aortic valve expose the cusps to
high mechanical and functional stress and inevitably cause
aortic stenosis [12,13]. Although pathology in the bicuspid
aorta begins with a congenital anomaly, the progression
of the disease continues with calcification, atherosclerosis,

and the inflammatory process, as in TAV [14]. However,
it is not effortless to understand which of these processes
has a large share or in what order it affects. Inflammation
may have the most crucial role in BAV degeneration.
Inflammatory process maintained by the presence of
increased shear stress includes various mechanisms such
as the collection of inflammatory cells and release of
cytokines, oxidative stress, and endothelial dysfunction
[15]. Various mechanisms, in different forms of the BAV,
may be heterogeneously responsible. While oxidative
stress is in the foreground in Type 1 BAV, endothelial
dysfunction becomes vital in Type 2 BAV [16]. However,
they all merge in the inflammatory process, which can
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Table 2. Laboratory parameters.

Parameters

All patients
n = 210

Group 1
BAV
n = 70

Group 2
TAV
n = 140

P-value

Serum glucose mg/dL

126.1 ± 52.8

135.2 ± 69.3

121.6 ± 41.8

0.079

HbA1c (%)

6.23 ± 1.2

6.54 ± 1.5

6.15 ± 0.9

0.084

Creatinine (mg/dL)

1.01 ± 0.40

0.97 ± 0.30

1.03 ± 0.44

0.301

Total cholesterol (mg/dL)

167.4 ± 43.6

159.8 ± 43.0

171.2 ± 43.7

0.074

Triglyceride (mg/dL)

122.8 ± 69.8

118.7 ± 59.0

124.9 ± 74.8

0.543

LDL cholesterol (mg/dL)

98.6 ± 35.3

94.7 ± 39.4

100.6 ± 33.0

0.249

HDL cholesterol (mg/dL)

45.4 ± 13.2

42.1 ± 13.7

47.0 ± 12.7

0.012

Hemoglobin (mg/dL)

11.7 ± 2.0

12.1 ± 1.7

11.4 ± 2.1

0.023

Neutrophil count, (× 10 /L)

4.80 ± 1.78

5.08 ± 1.82

4.65 ± 1.75

0.098

Lymphocyte count (× 10 /L)

1.59 ± 0.62

1.68 ± 0.61

1.55 ± 0.62

0.147

NLR

3.41 ± 1.77

3.54 ± 2.09

3.34 ± 1.59

0.441

Monocyte count (× 103/L)

0.59 ± 0.27

0.65 ± 0.26

0.55 ± 0.27

0.010

MHR

44.6 ± 14.2

17.6 ± 10.1

12.4 ± 6.6

<0.001

Platelet count (× 10 /L)

237.9 ± 81.3

243.4 ± 96.8

235.1 ± 72.6

0.488

MPV (fL)

10.5 ± 1.2

10.8 ± 1.2

10.4 ± 1.2

0.034

RDW

15.3 ± 2.1

15.2 ± 1.7

15.4 ± 2.2

0.598

3

3

3

NLR: neutrophil to lymphocyte ratio; MHR: monocyte to HDL-C ratio; RDW: red cell distribution width
Table 3. Comparison of baseline echocardiographic parameters.

Parameters

All patients
n = 210

Group 1
BAV
n = 70

Group 2
TAV
n = 140

P-value

LVEF (%)

49.8 ± 14.8

47.3 ± 16.4

51.0 ± 13.8

0.082

LVEDD (cm)

4.83 ± 0.72

4.97 ± 0.73

4.75 ± 0.71

0.041

LVESD (cm)

3.26 ± 0.92

3.45 ± 1.03

3.17 ± 0.85

0.039

Septal wall thickness (cm)

1.39 ± 0.24

1.39 ± 0.27

1.39 ± 0.22

0.814

Posterior wall thickness (cm)

1.30 ± 0.19

1.29 ± 0.23

1.30 ± 0.16

0.684

Aortic annulus (cm)

2.19 ± 0.22

2.26 ± 0.24

2.15 ± 0.21

0.001

LA (cm)

4.72 ± 0.69

4.62 ± 0.60

4.77 ± 0.73

0.171

Aortic peak velocity (m/s)

4.4 ± 0.5

4.4 ± 0.6

4.4 ± 0.5

0.711

Aortic max gradient (mmHg)

80.5 ± 20.7

81.0 ± 21.6

80.3 ± 20.3

0.815

Aortic mean gradient (mmHg)

49.4 ± 13.4

50.4 ± 14.0

48.9 ± 13.0

0.442

AVA (cm²)

0.67 ± 0.16

0.69 ± 0.18

0.66 ± 0.15

0.235

AVA index (cm²)

0.37 ± 0.09

0.38 ± 0.10

0.36 ± 0.08

0.416

sPAP (mmHg)

43.6 ± 17.4

39.9 ± 16.5

45.5 ± 17.6

0.028

LVEF: Left Ventricular Ejection Fraction, LVEDD: Left Ventricular End Diastolic Diameter, LVESD: Left
Ventricular End Systolic Diameter, LA: Left Atrium, LVH: Left Ventricular Hypertrophy, AVA: Aortic Valve
Area, sPAP: systolic Pulmonary Artery Pressure
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Table 4. Multivariate logistic regression analysis to detect
independent variables for the diagnosis of the bicuspid aortic
valve.
Parameters

Odds ratio

95% CI

P-value

Sex

0.87

0.41–1.81

0.716

Age

1.07

1.02–1.11

0.001

Total cholesterol

1.02

0.99–1.04

0.085

LDL cholesterol

0.98

0.95–1.00

0.206

NLR

1.02

0.85–1.24

0.780

MHR

0.94

0.90–0.98

0.005

DM

1.04

0.38–2.83

0.939

HT

1.82

0.66–4.98

0.241

Glucose

0.99

0.98–1.00

0.471

LVEF

1.00

0.98–1.03

0.649

NLR: neutrophil to lymphocyte ratio; MHR: monocyte to
HDL-C ratio; DM: Diabetes Mellitus; HT: Hypertension; LVEF:
Left Ventricular Ejection Fraction

cause subsequent changes, such as tissue remodeling and
calcification.
Few studies have compared clinical and
pathopsychological profiles in age-matched cohorts
between BAV and TAV stenosis. Differences between BAV
and TAV stenosis, such as the predominance of associated
cardiovascular risk factors, associated aortapathyes, or
variations in the size of the aortic annulus, may affect
clinical outcomes of aortic valve replacement [17].
Additionally, it should be noted that the reason for the
occurrence of AS at an earlier age in BAV may be that the
inflammatory process may be more dominant than TAV.
In our study, although traditional risk factors are similar
except for the patients’ ages, the earlier development of
degeneration in the BAV group also supports the role of
inflammation.
Monocytes are the reservoir of several cytokines
and molecules that associate with endothelial cells,
attending to aggravation of inflammatory pathways [18].
Inflammation plays an essential role in the development
and progression of atherosclerosis, and its effect in
many disease pathophysiologies has been demonstrated.
Since tissue macrophages originate from circulating
monocytes, the number of circulating monocytes and
monocyte subsets with different properties has attracted
attention in both atherosclerosis and valvular disease
studies [19]. Moreover, HDL reduces the prooxidant
and proinflammatory consequences of monocytes
by preventing the displacement of macrophages and
oxidation of low-density lipoprotein molecules, and also

by promoting the flow of cholesterol from these cells [20].
For the reasons mentioned above, it is very reasonable to
use a single marker, MHR, as an inflammatory marker by
proportioning these two separate markers, monocyte, and
HDL-C.
MHR was found to be related to cardiovascular diseases
[21], including stent thrombosis in STEMI [22], coronary
artery ectasia [23], and bare-metal stent restenosis
[24]. A significant association between MHR levels and
inflammation was demonstrated by the study of Acikgoz et
al. [25]; thus, it has been extensively investigated in other
diseases associated with inflammation. Moreover, it has
been shown to be a new potential marker for predicting
abdominal aortic aneurysm (AAA) size in asymptomatic
patients. Çağlı et al. showed that MHR was independently
associated with the AAA size after dividing 120
asymptomatic AAA patients into two groups according to
the MHR median value (54.3 ± 10.6 mm vs 62.0 ± 12.4
mm, P < 0.001, respectively) [26].
Diagnostic value of MHR has been reported by Demir
et al. in rheumatic mitral stenosis (RMS) [27]. In their
study, as mentioned earlier, in which 368 patients with
RMS were included, it was shown that MHR increased
in proportion to the severity of stenosis in the RMD
group compared to the control group. They found MHR
(odds ratio: 1.118 [95% CI: 1.018–1.228]; P = 0.019)
as the independent predictor of the presence of RMS
together with the left atrial diameter and CRP. Similarly,
Pamukcu et al. demonstrated that the presence of mitral
annular calcification was associated with higher MHR,
and MHR was significantly correlated with mitral annular
calcification [28].
The purpose of our study was to describe the
relationship between MHR, which effectively predicts
inflammation and severe BAV stenosis. Compatible with
previous studies on mitral stenosis, increased MHR was
found to be related to the BAV, in which inflammation
plays an essential role in its pathophysiology. However,
in our study, unlike Demir et al.’s [27], rheumatic severe
aortic stenosis was not included in the study. Bicuspid and
tricuspid AS patients were compared, but inflammation
plays a role in the pathophysiology of both these two
groups. We hypothesized that inflammation in BAV
stenosis is more severe than TAV stenosis. Nevertheless,
in similarity with our results, inflammation may be
considered to be more prevalent in BAV, because most of
the time, BAV is not alone, it should be regarded as part
of the ‘bicuspid aortic valve syndrome’. In the present
study, no significant difference was found between the
two groups in terms of another important marker of
inflammation, NLR. In most NLR studies, disease and
control groups were compared and higher in NLR disease
groups. In our study, both groups consisted of severe aortic
stenosis groups where inflammation played an important
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role. In addition, another explanation may be that the
primary purpose of the present study was not to compare
NLR. Another inflammation-related parameter, MPV,
was statistically higher in the BAV group. Elevated MPV
means more substantial platelet size, a pointer of platelet
activations and functions that are considered a risen risk
of cardiovascular disorder. Prior researches have revealed
that platelet activation increased since shear stress caused
by turbulence flow in the stenotic valve in AS patients
[29,30].
In our study, as in other studies, severe AS developed
in the BAV group at an earlier age than TAV. Similar to
our study, echocardiographic studies have shown that
degeneration typically begins in the second decade in
most middle-aged patients with BAV stenosis [31]. This
early degeneration may be linked to more aggressive
inflammatory changes secondary to augmented
macrophage infiltration and neovascularization [32].
Our study has some limitations. Firstly, it was a singlecenter retrospective study. Secondly, we measured MHR

only at baseline rather than the use of several measurements
taken at different time points, so serial MHR variations were
not evaluated. Thirdly, the impact of other inflammatory
markers, such as CRP, has not been evaluated due to a
lack of data. Finally, due to the retrospective design of the
study, we did not have information about diabetes drugs
that may affect inflammation parameters.
In conclusion, to our knowledge, our study showed
the important relationship between monocyte to HDL-C
ratio and bicuspid aortic valve for the first time in the
literature. MHR can be calculated easily from the routine
blood parameters, and also this parameter can be an
essential predictor for patients with BAV who have a
high inflammatory risk and a high rate of progression to
severe aortic stenosis. In light of our findings, large-scale
prospective studies are needed to investigate the effect of
antiinflammatory treatments on early BAV stenosis.
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